Compounds > isradipine
Page last updated: 2024-10-29

isradipine and Hyperlipoproteinemia

isradipine has been researched along with Hyperlipoproteinemia in 2 studies

Isradipine: A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.

Research Excerpts

ExcerptRelevanceReference
"5 mg isradipine on the low density lipoproteins (LDL) entry into the carotid and femoral arteries of 12 hypertensive patients with primary hyperlipoproteinemia (total cholesterol >6."5.08Isradipine lowers human arterial low density lipoprotein retention in vivo. ( Fitscha, P; Kritz, H; O'Grady, J; Sinzinger, H, 1998)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Pirich, C1
Fitscha, P2
Schmid, P1
Sinzinger, H2
Kritz, H1
O'Grady, J1

Trials

1 trial available for isradipine and Hyperlipoproteinemia

ArticleYear
Isradipine lowers human arterial low density lipoprotein retention in vivo.
    Prostaglandins, leukotrienes, and essential fatty acids, 1998, Volume: 59, Issue:5

    Topics: Adult; Antihypertensive Agents; Arteries; Blood Pressure; Calcium Channel Blockers; Carotid Arteries

1998

Other Studies

1 other study available for isradipine and Hyperlipoproteinemia

ArticleYear
Isradipine decreases the entry of radioiodine-labelled low-density lipoproteins into the arterial wall.
    Blood pressure. Supplement, 1994, Volume: 1

    Topics: Adult; Angiography; Arteries; Blood Pressure; Female; Gamma Rays; Humans; Hyperlipoproteinemias; Hyp

1994